IP Library Granted Patent US 12,516,088
Granted Patent B2
US 12,516,088 · App. 17/252,228 · Granted Jan 6, 2026

Fusion fragment chimeric antigen receptors and uses thereof

Inventors: Otto O. Yang (Los Angeles, CA); Balamurugan Arumugam (Los Angeles, CA)
Assignee: The Regents of the University of California
C07K14/15A61K35/28A61K40/10A61K40/31A61K40/46C07K14/7051C07K14/70517C12N15/62C12N15/85
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,516,088
App. No.
17/252,228
Granted
Jan 6, 2026
Kind
B2
Abstract

Disclosed herein are fusion fragment chimeric antigen receptors (FF-CARs), engineered cells expressing FF-CARs, and methods of using thereof to treat, reduce, or inhibit infections by enveloped viruses in subjects.

Claims (15)

1 . An expression vector comprising a nucleic acid sequence that encodes a chimeric antigen receptor consisting of an amino acid sequence as set forth in SEQ ID NO: 18 or SEQ ID NO: 20.

2 . An expression vector comprising a nucleic acid sequence that encodes a chimeric antigen receptor, wherein the nucleic acid sequence is SEQ ID NO: 17 or SEQ ID NO: 19.

3 . A cell comprising an expression vector according to claim 1 .

4 . The cell according to claim 3 , wherein the cell is a B cell, a T cell, a natural killer T cell, a hematopoietic stem cell, or a hematopoietic progenitor cell.

5 . A cell that is the progeny of the cell of claim 3 .

6 . The cell according to claim 3 , wherein the cell expresses the chimeric antigen receptor encoded by the expression vector.

7 . A method of treating, reducing, or inhibiting HIV-1 in a subject, which comprises transplanting one or more cells according to claim 3 , in the subject.

8 . A method of killing an infected cell infected with HIV-1, which comprises contacting the infected cell with one or more cells according to claim 3 .

9 . The method according to claim 7 , wherein the subject is human.

10 . A cell comprising an expression vector according to claim 2 .

11 . The cell according to claim 10 , wherein the cell is a B cell, a T cell, a natural killer T cell, a hematopoietic stem cell, or a hematopoietic progenitor cell.

12 . A cell that is the progeny of the cell of claim 11 .

13 . The cell according to claim 12 , wherein the cell expresses the chimeric antigen receptor encoded by the expression vector.

14 . A chimeric antigen receptor encoded by the expression vector according to claim 1 .

15 . A chimeric antigen receptor encoded by the expression vector according to claim 2 .

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 6, 2021
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054908/0429 →
Continuity (2)
Provisional Application 62685313 · Jun 15, 2018
Related Publication 20210252068A1 · Aug 19, 2021
References Cited (26)
US 9951118B2 · Kitchen · 2018 [cited by examiner]
US 20110263830A1 · Goetsch · 2011 [cited by examiner]
US 20110269676A1 · Jiang · 2011 [cited by examiner]
US 20160194375A1 · Kitchen · 2016 [cited by examiner]
US 20170267756A1 · Riddell · 2017 [cited by examiner]
WO 2000040616 · 2000 [cited by applicant]
WO 2005018666A1 · 2005 [cited by applicant]
WO 2011140092 · 2011 [cited by applicant]
WO 2015017755 · 2015 [cited by applicant]
WO 2019126464 · 2019 [cited by applicant]
Gacerez, Albert T., Benjamine Arellano, and Charles L. Sentman. “How chimeric antigen receptor design affects adoptive T cell therapy.” Journal of cellular physiology 231.12 (2016): 2590-2598. (Year: 2016). [cited by examiner]
White JM, Delos SE, Brecher M, Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol. May-Jun. 2008;43(3):189-219. (Year: 2008). [cited by examiner]
Egelhofer, Marc, et al. “Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.” Journal of virology 78.2 (2004): 568-575. (Year: 2004). [cited by examiner]
Wild, Carl T., et al. “Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.” Proceedings of the National Academy of Sciences 9… [cited by examiner]
Extended European Search report received in EP19818624.9, mailed Feb. 28, 2022. [cited by applicant]
Chupradit et al., Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era, Sep. 29, 2017, p. 281, vol. 9, No. 10, Publisher: Viruses. [cited by applicant]
Zhen et al., Chimeric antigen receptor engineered stem cells: a novel HIV therapy, Mar. 1, 2017, pp. 401-410, vol. 9, No. 5, Publisher: Immunotherapy. [cited by applicant]
International Search Report received in PCT/US2019/037048, mailed Nov. 18, 2019. [cited by applicant]
Written Opinion received in PCT/US2019/037048, mailed Nov. 18, 2019. [cited by applicant]
Halldorsson, et al., “Shielding and activation of a viral membrane fusion protein”, Jan. 24, 2018, p. 349, vol. 9, Publisher: Nat Commun. [cited by applicant]
Harrison, “Viral membrane fusion”, Jul. 2008, pp. 690-698, vol. 15, No. 7, Publisher: Nature structural & molecular biology. [cited by applicant]
Kielian, “Mechanisms of Virus Membrane Fusion Proteins”, Nov. 2014, pp. 7-89, vol. 1, No. 1, Publisher: Annual review of virology. [cited by applicant]
MacLean, et al., “A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells”, Oct. 1, 2014, pp. 341-348, vol. 43, No. 5, Publisher: Journal of medical primatology. [cited by applicant]
Sanders et al., “Mutational Analyses and Natural Variability of the gp41 Ectodomain”, Dec. 2002, pp. 1-23, Publisher: HIV Molecular Immunology. [cited by applicant]
White, et al., “Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme”, May 2008, pp. 189-219, vol. 43, No. 3, Publisher: Critical reviews in biochemistry and molecular biolo… [cited by applicant]
Zhen, et al., “Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS”, Dec. 28, 2017, p. e1006753, vol. 13, No. 12, Publisher: PL… [cited by applicant]